236 related articles for article (PubMed ID: 38254627)
1. Cimetidine Does Not Inhibit 5-Aminolevulinic Acid Synthase or Heme Oxygenase Activity: Implications for Treatment of Acute Intermittent Porphyria and Erythropoietic Protoporphyria.
Yasuda M; Lee S; Gan L; Bergonia HA; Desnick RJ; Phillips JD
Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38254627
[TBL] [Abstract][Full Text] [Related]
2. Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria.
Schuurmans MM; Hoffmann F; Lindberg RL; Meyer UA
Hepatology; 2001 May; 33(5):1217-22. PubMed ID: 11343251
[TBL] [Abstract][Full Text] [Related]
3. [Porphyrias-what is verified?].
Stölzel U; Kubisch I; Stauch T
Internist (Berl); 2018 Dec; 59(12):1239-1248. PubMed ID: 30328490
[TBL] [Abstract][Full Text] [Related]
4. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
[TBL] [Abstract][Full Text] [Related]
5. Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.
Linenberger M; Fertrin KY
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):400-410. PubMed ID: 33275677
[TBL] [Abstract][Full Text] [Related]
6. Clinical Guide and Update on Porphyrias.
Stölzel U; Doss MO; Schuppan D
Gastroenterology; 2019 Aug; 157(2):365-381.e4. PubMed ID: 31085196
[TBL] [Abstract][Full Text] [Related]
7. Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.
Yasuda M; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):332-341. PubMed ID: 30737139
[TBL] [Abstract][Full Text] [Related]
8. Heme biosynthesis and the porphyrias.
Phillips JD
Mol Genet Metab; 2019 Nov; 128(3):164-177. PubMed ID: 31326287
[TBL] [Abstract][Full Text] [Related]
9. Novel Treatment Using Cimetidine for Erythropoietic Protoporphyria in Children.
Tu JH; Sheu SL; Teng JM
JAMA Dermatol; 2016 Nov; 152(11):1258-1261. PubMed ID: 27410690
[TBL] [Abstract][Full Text] [Related]
10. Induction of hepatic aminolevulinate acid synthetase activity by isoflurane in a genetic model for erythropoietic protoporphyria.
Buzaleh AM; Morán-Jiménez MJ; Garcia-Bravo M; Sampedro A; Batlle AM; Enriquez de Salamanca R; Fontanellas A
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):38-44. PubMed ID: 19268000
[TBL] [Abstract][Full Text] [Related]
11. Porphyria: What Is It and Who Should Be Evaluated?
Edel Y; Mamet R
Rambam Maimonides Med J; 2018 Apr; 9(2):. PubMed ID: 29553924
[TBL] [Abstract][Full Text] [Related]
12. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
[TBL] [Abstract][Full Text] [Related]
13. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.
Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868
[TBL] [Abstract][Full Text] [Related]
14. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
[TBL] [Abstract][Full Text] [Related]
15. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
[TBL] [Abstract][Full Text] [Related]
16. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
Sardh E; Harper P; Andersson DE; Floderus Y
Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
[TBL] [Abstract][Full Text] [Related]
17. Cimetidine for erythropoietic protoporphyria.
Heerfordt IM; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102793. PubMed ID: 35245673
[TBL] [Abstract][Full Text] [Related]
18. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.
Yasuda M; Chen B; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):320-331. PubMed ID: 30594473
[TBL] [Abstract][Full Text] [Related]
19. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.
Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ
Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812
[TBL] [Abstract][Full Text] [Related]
20. Alteration of mRNA levels of delta-aminolevulinic acid synthase, ferrochelatase and heme oxygenase-1 in griseofulvin induced protoporphyria mice.
Inafuku K; Takamiyagi A; Oshiro M; Kinjo T; Nakashima Y; Nonaka S
J Dermatol Sci; 1999 Apr; 19(3):189-98. PubMed ID: 10215191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
